OSR Holdings, Inc. (NASDAQ:OSRH) Short Interest Update

OSR Holdings, Inc. (NASDAQ:OSRH) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 1,094,583 shares, an increase of 101.1% from the December 31st total of 544,307 shares. Based on an average daily volume of 4,985,615 shares, the short-interest ratio is presently 0.2 days. Currently, 10.8% of the shares of the stock are sold short. Currently, 10.8% of the shares of the stock are sold short. Based on an average daily volume of 4,985,615 shares, the short-interest ratio is presently 0.2 days.

OSR Price Performance

Shares of NASDAQ:OSRH opened at $0.58 on Friday. OSR has a 1 year low of $0.45 and a 1 year high of $11.84. The firm has a market capitalization of $14.99 million, a PE ratio of -0.52 and a beta of 1.42. The business’s 50 day moving average price is $0.66 and its 200-day moving average price is $0.67.

OSR (NASDAQ:OSRH) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.63 million during the quarter.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OSRH. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a research report on Monday, December 29th. Wall Street Zen upgraded OSR to a “sell” rating in a research report on Saturday, October 18th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, OSR presently has an average rating of “Sell”.

Institutional Trading of OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP acquired a new stake in OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR at the end of the most recent quarter. Institutional investors own 55.30% of the company’s stock.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.